

Title (en)
PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS

Title (de)
PH-WERT-ABHÄNGIGE NMDA-REZEPTORANTAGONISTEN

Title (fr)
ANTAGONISTES DU RECEPTEUR NMDA DEPENDANT DU PH

Publication
EP 1436258 A4 20050323 (EN)

Application
EP 02719157 A 20020308

Priority
• US 0207033 W 20020308
• US 27420501 P 20010308

Abstract (en)
[origin: WO02072542A2] NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Preferably the compounds provided herein are allosteric NMDA inhibitors.

IPC 1-7
C07D 201/00

IPC 8 full level
A61K 31/136 (2006.01); **A61K 31/138** (2006.01); **A61K 31/18** (2006.01); **A61K 31/222** (2006.01); **A61K 31/417** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/421** (2006.01); **A61K 31/438** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/445** (2006.01); **A61K 31/4515** (2006.01); **A61K 31/4745** (2006.01); **A61K 31/495** (2006.01); **A61K 31/496** (2006.01); **A61P 7/00** (2006.01); **A61P 25/02** (2006.01); **A61P 25/04** (2006.01); **A61P 25/08** (2006.01); **A61P 25/14** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07B 53/00** (2006.01); **C07C 213/02** (2006.01); **C07C 217/34** (2006.01); **C07C 303/40** (2006.01); **C07C 311/08** (2006.01); **C07C 311/21** (2006.01); **C07D 263/24** (2006.01)

CPC (source: EP US)
A61P 7/00 (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 217/34** (2013.01 - EP US); **C07C 311/08** (2013.01 - EP US); **C07C 311/21** (2013.01 - EP US); **C07D 263/24** (2013.01 - EP US)

Citation (search report)
• [DA] US 5962472 A 19991005 - BOURSON ANNE [FR], et al
• [DA] MOTT, DAVID D. ET AL., NATURE NEUROSCIENCE, vol. 1, no. 8, 1998, pages 659 - 667, XP002304507
• See references of WO 02072542A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02072542 A2 20020919; **WO 02072542 A3 20030227**; AU 2002250256 B2 20080403; CA 2440284 A1 20020919; EP 1436258 A2 20040714; EP 1436258 A4 20050323; JP 2005506292 A 20050303; US 2004138502 A1 20040715; US 2009023791 A1 20090122; US 7375136 B2 20080520

DOCDB simple family (application)
US 0207033 W 20020308; AU 2002250256 A 20020308; CA 2440284 A 20020308; EP 02719157 A 20020308; JP 2002571458 A 20020308; US 15163308 A 20080508; US 46982404 A 20040225